BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.12M | 3.02M | 3.03M | 1.96M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | 3.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.55M | 3.54M | 3.49M | 2.38M | 2.35M |
| Operating Income | -3.55M | -3.54M | -3.49M | -2.38M | -2.35M |
| Income Before Tax | -2.61M | -3.24M | -2.95M | -2.15M | -2.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.61 | -3.24 | -2.95 | -2.15 | -2.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -399.30K | -355.70K | -355.90K | 5.60K | 420.00K |
| Net Income | -3.01M | -3.59M | -3.31M | -2.15M | -1.65M |
| EBIT | -3.55M | -3.54M | -3.49M | -2.38M | -2.35M |
| EBITDA | -537.50K | -1.05M | -1.81M | -2.37M | -2.33M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 480.72M | 464.10M | 452.84M | 436.96M | 411.62M |
| Average Diluted Shares Outstanding | 498.01M | 464.10M | 452.84M | 436.96M | 411.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
